🇺🇸 FDA
Pipeline program

Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg

D5892C00016

Approved small_molecule completed

Quick answer

Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg for Chronic Obstructive Pulmonary Disease (COPD) is a Approved program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials